Published in Trop Med Int Health on March 29, 2010
Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proc Natl Acad Sci U S A (2011) 2.83
Rationale for short course primaquine in Africa to interrupt malaria transmission. Malar J (2012) 1.35
Improving malaria control in West Africa: interruption of transmission as a paradigm shift. Acta Trop (2011) 0.96
Baseline in vitro activities of the antimalarials pyronaridine and methylene blue against Plasmodium falciparum isolates from Kenya. Antimicrob Agents Chemother (2011) 0.90
Repositioning: the fast track to new anti-malarial medicines? Malar J (2014) 0.83
The antimalarial activities of methylene blue and the 1,4-naphthoquinone 3-[4-(trifluoromethyl)benzyl]-menadione are not due to inhibition of the mitochondrial electron transport chain. Antimicrob Agents Chemother (2013) 0.81
Plasmodium drug targets outside the genetic control of the parasite. Curr Pharm Des (2013) 0.79
Alternatives to currently used antimalarial drugs: in search of a magic bullet. Infect Dis Poverty (2016) 0.75
Insights from the genome of the biotrophic fungal plant pathogen Ustilago maydis. Nature (2006) 5.52
Acupuncture and knee osteoarthritis: a three-armed randomized trial. Ann Intern Med (2006) 4.42
Natural malaria infection in Anopheles gambiae is regulated by a single genomic control region. Science (2006) 4.38
Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology (2003) 3.93
Longevity of materials for pit and fissure sealing--results from a meta-analysis. Dent Mater (2011) 3.56
Identification of a common gene expression signature in dilated cardiomyopathy across independent microarray studies. J Am Coll Cardiol (2006) 2.73
Magnetic resonance colonography for the detection of colorectal neoplasia in asymptomatic adults. Gastroenterology (2013) 2.71
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol (2010) 2.66
Multiple levels of regulation of the interleukin-6 system in stroke. Stroke (2003) 2.61
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood (2008) 2.46
Community factors associated with malaria prevention by mosquito nets: an exploratory study in rural Burkina Faso. Trop Med Int Health (2002) 2.37
Severe anaemia in west African children: malaria or malnutrition? Lancet (2003) 2.31
Risk factors of infant and child mortality in rural Burkina Faso. Bull World Health Organ (2004) 2.24
GlobalANCOVA: exploration and assessment of gene group effects. Bioinformatics (2007) 2.24
Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med (2013) 2.07
Course of platelet activation markers after ischemic stroke. Stroke (2002) 2.05
Factors affecting and affected by user acceptance of computer-based nursing documentation: results of a two-year study. J Am Med Inform Assoc (2003) 2.05
Pathogenicity determinants in smut fungi revealed by genome comparison. Science (2010) 2.03
Compliance of young children with ITN protection in rural Burkina Faso. Malar J (2006) 1.96
Human papillomavirus vaccination in Africa. Lancet (2011) 1.96
Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol (2012) 1.90
Malaria, anemia, and malnutrition in african children--defining intervention priorities. J Infect Dis (2006) 1.90
Determinants of utilisation of maternal care services after the reduction of user fees: a case study from rural Burkina Faso. Health Policy (2010) 1.85
Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther (2005) 1.82
The effect of community-based health insurance on the utilization of modern health care services: evidence from Burkina Faso. Health Policy (2008) 1.81
CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol (2008) 1.78
Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clin Pharmacol Ther (2003) 1.78
The effect of distance to health-care facilities on childhood mortality in rural Burkina Faso. Am J Epidemiol (2011) 1.78
Active sites of thioredoxin reductases: why selenoproteins? Proc Natl Acad Sci U S A (2003) 1.69
Multiple testing on the directed acyclic graph of gene ontology. Bioinformatics (2008) 1.69
A prospective randomized study to assess the efficacy of a surgical sealant to treat air leaks in lung surgery. Eur J Cardiothorac Surg (2009) 1.68
Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial. PLoS One (2009) 1.68
Decline of placental malaria in southern Ghana after the implementation of intermittent preventive treatment in pregnancy. Malar J (2007) 1.66
Malaria in rural Burkina Faso: local illness concepts, patterns of traditional treatment and influence on health-seeking behaviour. Malar J (2007) 1.65
Season of death and birth predict patterns of mortality in Burkina Faso. Int J Epidemiol (2005) 1.65
The Health and Demographic Surveillance System (HDSS) in Nouna, Burkina Faso, 1993-2007. Glob Health Action (2010) 1.64
The great failure of malaria control in Africa: a district perspective from Burkina Faso. PLoS Med (2007) 1.60
Anopheles gambiae APL1 is a family of variable LRR proteins required for Rel1-mediated protection from the malaria parasite, Plasmodium berghei. PLoS One (2008) 1.55
Measures of general and central obesity and risk of type 2 diabetes in a Ghanaian population. Trop Med Int Health (2012) 1.52
Pharmacokinetics of a netilmicin loading dose on the first postnatal day in preterm neonates with very low gestational age. Eur J Clin Pharmacol (2006) 1.51
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol (2009) 1.49
A compendium to ensure computational reproducibility in high-dimensional classification tasks. Stat Appl Genet Mol Biol (2004) 1.48
Long-term prophylactic treatment of attacks of vertigo in Menière's disease--comparison of a high with a low dosage of betahistine in an open trial. Acta Otolaryngol (2008) 1.48
Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother (2006) 1.47
Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia. Angew Chem Int Ed Engl (2005) 1.46
In vitro assessment of methylene blue on chloroquine-sensitive and -resistant Plasmodium falciparum strains reveals synergistic action with artemisinins. Antimicrob Agents Chemother (2005) 1.46
Local and International Implications of Schistosomiasis Acquired in Corsica, France. Emerg Infect Dis (2015) 1.45
Access to malaria treatment in young children of rural Burkina Faso. Malar J (2009) 1.41
Deceptive argumentation against diagnostic microdosing of anticancer drugs. Int J Cancer (2014) 1.41
Calcium load during administration of calcium carbonate or sevelamer in individuals with normal renal function. Nephrol Dial Transplant (2008) 1.41
Uncommon manifestation of a mixed-species malaria infection: cryptic falciparum malaria in a traveler with successfully treated tertian malaria. J Travel Med (2012) 1.40
Quantification of melanoma micrometastases in sentinel lymph nodes using real-time RT-PCR. J Invest Dermatol (2005) 1.39
Methylene blue as an antimalarial agent. Redox Rep (2003) 1.39
Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Malar J (2006) 1.37
Pattern of cause-specific childhood mortality in a malaria endemic area of Burkina Faso. Malar J (2006) 1.35
Effects of insecticide-treated bednets during early infancy in an African area of intense malaria transmission: a randomized controlled trial. Bull World Health Organ (2006) 1.35
CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS One (2009) 1.34
Diabetes mellitus type 2 in urban Ghana: characteristics and associated factors. BMC Public Health (2012) 1.33
Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum. Infect Immun (2006) 1.32
Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther (2006) 1.30
Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol (2013) 1.29
Patterns of malaria: cause-specific and all-cause mortality in a malaria-endemic area of west Africa. Am J Trop Med Hyg (2008) 1.28
Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum. Antimicrob Agents Chemother (2007) 1.28
Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]. Malar J (2005) 1.28
High prevalence of drug-resistance mutations in Plasmodium falciparum and Plasmodium vivax in southern Ethiopia. Malar J (2006) 1.27
High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol (2008) 1.27
Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proc Natl Acad Sci U S A (2009) 1.25
Prevalence and risk factors of malaria among children in southern highland Rwanda. Malar J (2011) 1.25
Exceptional diversity, maintenance of polymorphism, and recent directional selection on the APL1 malaria resistance genes of Anopheles gambiae. PLoS Biol (2011) 1.25